Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2020	Apr. 30, 2019
Current assets:
Cash and cash equivalents	$ 18,615	$ 32,006
Marketable securities	61,955	68,805
Research and development tax credit receivable	14,803	11,315
Prepaid expenses and other current assets	3,632	3,420
Total current assets	99,005	115,546
Right of use assets	1,497
Property and equipment, net	2,260	2,413
Other assets	173	173
Total assets	102,935	118,132
Current liabilities:
Accounts payable	2,951	2,860
Accrued expenses	4,876	5,647
Deferred revenue - current portion	1,343	9,545
Lease liability - current portion	592
Total current liabilities	9,762	18,052
Long-term liabilities:
Deferred revenue - net of current portion	2,500	3,342
Lease liability - net of current portion	926
Total long-term liabilities	3,426	3,342
Commitments and contingencies (Note 5)
Stockholders’ equity
Common stock, $0.001 par value, 100,000,000 authorized Shares issued and outstanding: 17,845,599 at January 31, 2020 and 17,277,750 at April 30, 2019	18	17
Additional paid-in capital	206,119	191,123
Accumulated deficit	(115,008)	(92,476)
Accumulated other comprehensive loss	(1,382)	(1,926)
Total stockholders’ equity	89,747	96,738
Total liabilities and stockholders’ equity	$ 102,935	$ 118,132